[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Southeast University, China\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":587},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,34,0,25,[9,39,73,104,127,150,174,198,223,251,273,291,315,341,351,369,389,409,424,450,471,494,515,541,568],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":27,"lastUpdatePostDateStruct":28,"startDateStruct":31,"completionDateStruct":33,"leadSponsor":35,"locationsCount":38},"100054104","validation-and-precision-treatment-of-inflammatory-subphenotypes-in-acute-respiratory-distress-syndrome-a-multicenter-cohort-study-100054104",false,"NCT07289711","Validation and Precision Treatment of Inflammatory Subphenotypes in Acute Respiratory Distress Syndrome: A Multicenter Cohort Study","VATIC","Inclusion Criteria:\n\n1. Age ≥ 18 years.\n2. ARDS with new Global definition.\n3. Onset of ARDS within 72 hours.\n\nExclusion Criteria:\n\n1. Refusal of informed consent by the patient's legally authorized representative.\n2. Patients expected to die within 24 hours\n3. Receiving extracorporeal membrane oxygenation at the time of recruitment","ALL","18 Years",{"count":20,"type":21},500,"ESTIMATED","OBSERVATIONAL","Acute respiratory distress syndrome (ARDS) is a common and life-threatening condition in intensive care units, characterized by substantial biological and clinical heterogeneity. Differences in patients' inflammatory responses, baseline immune function, and organ failure patterns contribute to variability in ARDS severity, treatment response, and clinical outcomes. Precision classification of ARDS based on biological and inflammatory characteristics may therefore be essential for improving patient outcomes. Previous analyses of randomized clinical trials have identified two reproducible inflammatory subphenotypes-\"hyperinflammatory\" and \"hypoinflammatory\"-which differ in organ dysfunction profiles, clinical trajectories, and responses to treatments such as fluid management strategies, corticosteroids, and ventilatory interventions. However, key uncertainties remain, including whether these inflammatory subphenotypes can be validated in Chinese ARDS populations, how various bedside prediction models perform in identifying these subphenotypes, and whether model-based subphenotype identification can guide individualized treatment decisions. This multicenter cohort study aims to: (1) validate inflammatory subphenotypes of ARDS using latent class analysis; (2) compare the predictive performance of existing bedside models for subphenotype identification; and (3) assess whether subphenotype assignment based on prediction models can guide individualized treatment strategies, including fluid management, PEEP titration, and corticosteroid use. In addition to these primary aims, the study may include other exploratory objectives, such as evaluating subphenotype stability over time, characterizing biological pathways associated with subphenotypes, and assessing additional treatment-response patterns to support future precision ARDS management strategies.",[25],"Acute Respiratory Distress Syndrome","RECRUITING","2026-07-09",{"date":29,"type":30},"2026-07-13","ACTUAL",{"date":32,"type":30},"2025-12-29",{"date":34,"type":21},"2026-12-31",{"name":36,"class":37},"Southeast University, China","OTHER",1,{"id":40,"slug":41,"hasResults":12,"nctId":42,"briefTitle":43,"officialTitle":44,"acronym":45,"eligibilityCriteria":46,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":47,"enrollmentInfo":48,"targetDuration":50,"studyType":22,"phases":4,"briefSummary":51,"conditions":52,"keywords":57,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":27,"lastUpdatePostDateStruct":67,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":4},"100053330","outer-membrane-vesicle-and-ferroptosis-related-signatures-in-sepsis-associated-acute-lung-injury-caused-by-extra-pulmonary-hypervirulent-klebsiella-pneumoniae-100053330","NCT07686887","Outer Membrane Vesicle and Ferroptosis-Related Signatures in Sepsis-Associated Acute Lung Injury Caused by Extra-Pulmonary Hypervirulent Klebsiella Pneumoniae","Circulating Bacterial Outer Membrane Vesicle Signatures and Ferroptosis-Related Biomarkers in Sepsis-Associated Acute Lung Injury Among Patients With Extra-Pulmonary Hypervirulent Klebsiella Pneumoniae Infection: A Prospective Observational Translational Cohort Study","OMV-FERRO-ALI","Inclusion Criteria:\n\n* Age 18-85 years .\n* Clinical suspicion of infection with acute organ dysfunction consistent with suspected sepsis at the time of enrollment, as determined by the treating clinical team.\n* Presumed extra-pulmonary source of infection at enrollment, including but not limited to hepatobiliary, urinary, intra-abdominal, skin and soft-tissue, vascular catheter-related, or primary bloodstream infection.\n* Blood cultures and\u002For clinically indicated source cultures obtained or ordered as part of routine clinical care.\n* Enrollment and first research blood collection completed within 6 hours after initiation of the clinical sepsis evaluation.\n* No evidence of acute lung injury at the index time point, according to the protocol-defined criteria.\n* Written informed consent obtained from the participant or legally authorized representative, unless an ethics-approved deferred-consent procedure is used.\n\nExclusion Criteria:\n\n* Suspected or confirmed primary pulmonary infection at enrollment, including community-acquired pneumonia, hospital-acquired pneumonia, ventilator-associated pneumonia, or aspiration pneumonia.\n\nAcute lung injury or acute respiratory distress syndrome present at the index time point.\n\n* Acute cardiogenic pulmonary edema, acute decompensated heart failure, or another condition that would preclude reliable adjudication of subsequent non-cardiogenic acute lung injury.\n* Recent inhalation injury, near-drowning, major thoracic trauma, or transfusion-related acute lung injury.\n* Previous enrollment in this study.\n* Inability to obtain informed consent from the participant or legally authorized representative when deferred-consent procedures are not permitted by the local ethics committee.","85 Years",{"count":49,"type":21},120,"28 Days","This prospective observational translational cohort study will investigate whether extra-pulmonary infection caused by hypervirulent Klebsiella pneumoniae (hvKP) is associated with an increased risk of sepsis-associated acute lung injury (SALI), compared with infection caused by classical Klebsiella pneumoniae (cKP). The study will further examine whether circulating bacterial outer membrane vesicle (OMV) signals and ferroptosis-related biomarker profiles are associated with subsequent SALI development.\n\nAdults with Sepsis-3 and microbiologically confirmed extra-pulmonary K. pneumoniae infection will be enrolled within 6 hours of sepsis recognition. Patients with acute lung injury at enrollment will be excluded from the primary cohort. Blood samples will be collected at enrollment, 24 hours, and 72 hours. Clinical isolates will undergo molecular characterization to classify infections as hvKP or cKP. The primary outcome will be new-onset SALI within 7 days after enrollment. A nested translational substudy will evaluate the effects of patient-isolate-derived OMVs on human pulmonary microvascular endothelial cells.\n\nThe study will not alter antimicrobial therapy, source control, respiratory support, fluid management, or any other aspect of routine clinical care.",[53,54,55,56],"Sepsis","Acute Lung Injury(ALI)","Klebsiella Pneumoniae Infection","Hypervirulent Klebsiella Pneumoniae Infection",[58,59,60,61,62,63,64,65],"Hypervirulent Klebsiella pneumoniae","Extra-pulmonary infection","Sepsis-associated acute lung injury","Bacterial outer membrane vesicles","Ferroptosis","Pulmonary microvascular endothelial cells","Lipid peroxidation","Endothelial barrier dysfunction","NOT_YET_RECRUITING",{"date":29,"type":30},{"date":69,"type":21},"2026-07-06",{"date":71,"type":21},"2030-07-30",{"name":36,"class":37},{"id":74,"slug":75,"hasResults":12,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":79,"eligibilityCriteria":80,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":81,"enrollmentInfo":82,"targetDuration":4,"studyType":84,"phases":85,"briefSummary":87,"conditions":88,"keywords":92,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":38},"100644856","anti-bloating-patch-for-postoperative-gastric-distension-after-cardiac-surgery-100644856","NCT07677423","Anti-Bloating Patch for Postoperative Gastric Distension After Cardiac Surgery","Efficacy of an Anti-Bloating Patch for Postoperative Gastric Distension After Cardiac Surgery: A Randomized Controlled Trial Using Quantitative Gastric Bubble Imaging Analysis","ABP-CS","Inclusion Criteria:\n\n* Age ≥18 years\n* Undergoing elective cardiac surgery\n* Postoperative chest radiographs available for gastric bubble area assessment\n* Able to provide written informed consent or have consent provided by a legally authorized representative\n* Expected postoperative intensive care unit admission\n\nExclusion Criteria:\n\n* Previous major gastrointestinal surgery affecting gastric anatomy or motility\n* Known gastrointestinal obstruction, perforation, or severe gastrointestinal disease\n* Severe hepatic or renal dysfunction judged unsuitable by the investigators\n* Known allergy or hypersensitivity to components of the anti-bloating patch\n* Participation in another interventional clinical trial within the previous 30 days\n* Pregnancy or lactation\n* Inability to complete study assessments or follow study procedures","80 Years",{"count":83,"type":21},150,"INTERVENTIONAL",[86],"NA","Postoperative gastric distension is a common gastrointestinal complication after cardiac surgery and may delay recovery, prolong intensive care unit (ICU) stay, and reduce patient comfort. Anti-bloating patches are widely used in clinical practice to promote gastrointestinal function recovery; however, high-quality evidence regarding their effectiveness in cardiac surgical patients remains limited.\n\nThis randomized controlled trial aims to evaluate the efficacy and safety of an anti-bloating patch in reducing postoperative gastric distension after cardiac surgery. Adult patients undergoing cardiac surgery will be randomly assigned to receive either standard perioperative care alone or standard perioperative care plus anti-bloating patch therapy. Gastric bubble area will be quantitatively measured using chest radiographs and image analysis software.\n\nThe primary outcome is the change in gastric bubble area on postoperative day 1 compared with baseline. Secondary outcomes include gastric bubble area on postoperative day 1, percentage change in gastric bubble area, abdominal distension score, time to first flatus, time to first bowel movement, gastric drainage volume, time to oral feeding, ICU length of stay, postoperative hospital length of stay, and patch-related adverse events.\n\nThe results of this study may provide evidence for the use of anti-bloating patches as an adjunctive intervention to enhance postoperative gastrointestinal recovery in patients undergoing cardiac surgery.",[89,90,91],"Postoperative Gastric Distension","Postoperative Gastrointestinal Dysfunction","Cardiac Surgery",[93,89,94,91,95],"Anti-Bloating Patch","Gastric Bubble Area","Gastrointestinal Dysfunction","2026-06-27",{"date":98,"type":30},"2026-06-30",{"date":100,"type":21},"2026-07-01",{"date":102,"type":21},"2027-07-01",{"name":36,"class":37},{"id":105,"slug":106,"hasResults":12,"nctId":107,"briefTitle":108,"officialTitle":108,"acronym":109,"eligibilityCriteria":110,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":111,"targetDuration":4,"studyType":84,"phases":113,"briefSummary":115,"conditions":116,"keywords":118,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":121,"lastUpdatePostDateStruct":122,"startDateStruct":123,"completionDateStruct":124,"leadSponsor":126,"locationsCount":38},"100639468","phase-3-dexamethasone-treatment-for-sepsis-associated-acute-respiratory-distress-syndrome-a-multicenter-randomised-double-blinded-controlled-trial-100639468","NCT07576660","Dexamethasone Treatment for Sepsis-associated Acute Respiratory Distress Syndrome: a Multicenter, Randomised, Double-blinded, Controlled Trial","DEFEND","Inclusion Criteria:\n\n1. Age 18 years or older\n2. Suspected or confirmed infection\n3. Receipt of invasive mechanical ventilation with a positive end-expiratory pressure (PEEP) of at least 5 cm H₂O, noninvasive positive-pressure ventilation with a PEEP of at least 5 cm H₂O, or high-flow nasal oxygen therapy with a flow rate of at least 30 L\u002Fmin\n4. Acute-onset ARDS, defined as ARDS diagnosed for at least 6 hours but no more than 72 hours, according to the following criteria:\n\n(1) New or worsening respiratory symptoms or respiratory failure (2) Pulmonary infiltrates on chest radiography or computed tomography, or B-lines or consolidation on lung ultrasonography, not fully explained by pleural effusion, lobar or whole-lung collapse or atelectasis, or pulmonary nodules. Patients with unilateral pulmonary infiltrates, B-lines, or consolidation are eligible (3) Respiratory failure not fully explained by cardiac failure or fluid overload (4) Hypoxemia defined as PaO₂\u002FFiO₂ of 300 mm Hg or less, or SpO₂\u002FFiO₂ of 315 or less, with SpO₂ no greater than 97%.\n\nExclusion Criteria:\n\n1. Pregnancy\n2. Planned withdrawal of life-sustaining treatment within the next 24 hours\n3. Current hospitalization for more than 7 days before screening;\n4. Clinical improvement within the 48 hours before randomization, based on the investigator's overall assessment\n5. Highly suspected or confirmed COVID-19 infection\n6. Severe chronic obstructive pulmonary disease, defined as a PaCO₂ ≥ 60 mmHg in a stable condition, or the need for long-term oxygen therapy, excluding CPAP\u002FBiPAP prescribed exclusively for sleep-disordered breathing.\n7. Congestive heart failure (NYHA III-IV)\n8. A definite clinical indication for high-dose corticosteroids at screening, defined as a maximum daily dose exceeding hydrocortisone 200 mg or an equivalent glucocorticoid dose\n9. Contraindications to short-term dexamethasone, including untreated systemic fungal infection, active tuberculosis, active viral hepatitis, or major upper gastrointestinal bleeding\n10. Known hypersensitivity to dexamethasone\n11. Participation in another interventional clinical trial within the previous 30 days",{"count":112,"type":21},1704,[114],"PHASE3","Acute respiratory distress syndrome (ARDS) is a major cause of acute hypoxemic respiratory failure in critically ill patients and is associated with substantial mortality. Current management is largely supportive, and no pharmacologic therapy has been shown consistently to reduce mortality in a broad population of patients with ARDS. Inflammation plays a central role in the pathogenesis of ARDS. Excessive inflammatory activation contributes to alveolar-capillary injury, impaired gas exchange, and progression of organ dysfunction. Glucocorticoids may mitigate these processes and have been associated in some studies with improved clinical outcomes, including shorter duration of mechanical ventilation. However, the effect of glucocorticoids on survival remains uncertain.\n\nARDS is a heterogeneous syndrome with diverse etiologies, and treatment response may vary according to the underlying cause. A post hoc analysis of the Dex-ARDS trial suggested that the treatment effect of glucocorticoids may be greater in ARDS caused by pneumonia or extrapulmonary sepsis. In a cross-sectional survey of 135 patients with ARDS from 20 ICUs in China, pneumonia- and extrapulmonary sepsis-associated ARDS accounted for 77.6% of cases, indicating that these are the predominant etiologic subtypes encountered in clinical practice in China. More importantly, compared with ARDS attributable to other causes, pneumonia- and extrapulmonary sepsis-associated ARDS has been associated with higher mortality, suggesting a greater disease burden, worse prognosis, and a more urgent need for improved treatment strategies. On this basis, the present trial will enroll patients with ARDS caused by sepsis, including pneumonia and extrapulmonary sepsis.\n\nThe primary hypothesis of this study is that, among patients with sepsis-associated ARDS, dexamethasone plus usual care, as compared with placebo plus usual care, will reduce 90-day all-cause mortality. We therefore designed a multicenter, randomized, double-blind, controlled trial to evaluate the clinical efficacy of dexamethasone in patients with sepsis-associated ARDS. The primary objective is to compare dexamethasone plus usual care with placebo plus usual care with respect to 90-day all-cause mortality.",[117],"Acute Respiratory Distress Syndrome (ARDS)",[119,53,120],"Acute respiratory distress syndrome","Dexamethasone","2026-06-25",{"date":98,"type":30},{"date":100,"type":21},{"date":125,"type":21},"2030-09-30",{"name":36,"class":37},{"id":128,"slug":129,"hasResults":12,"nctId":130,"briefTitle":131,"officialTitle":132,"acronym":4,"eligibilityCriteria":133,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":47,"enrollmentInfo":134,"targetDuration":4,"studyType":84,"phases":136,"briefSummary":137,"conditions":138,"keywords":139,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":142,"lastUpdatePostDateStruct":143,"startDateStruct":145,"completionDateStruct":147,"leadSponsor":149,"locationsCount":4},"100633554","phase-3-study-of-xuanbai-shengmai-decoction-in-the-treatment-of-acute-respiratory-distress-syndrome-100633554","NCT07528196","Study of Xuanbai Shengmai Decoction in the Treatment of Acute Respiratory Distress Syndrome","Clinical Collaboration Project of Integrated Traditional Chinese and Western Medicine for Major and Intractable Diseases - A Multicenter, Randomized Controlled Trial of Xuanbai Shengmai Decoction in the Treatment of Acute Respiratory Distress Syndrome","Inclusion Criteria:\n\n1. Met the diagnostic criteria for ARDS according to the 2023 updated global definition.\n2. Within 48 hours of meeting the diagnostic criteria.\n3. Aged ≥ 18 years and ≤ 85 years.\n\nExclusion Criteria:\n\n1. Did not meet the diagnostic criteria.\n2. Pregnant or lactating women.\n3. Patients with gastrointestinal dysfunction (including gastrointestinal bleeding, severe intra-abdominal hypertension, severe intestinal obstruction, etc.), resulting in the inability to administer medication via nasogastric\u002Fnasoenteric tube or orally within 48 hours after enrollment.\n4. SOFA score \\> 13.\n5. Hypersensitivity to the study drugs.\n6. Withdrawal of treatment.",{"count":135,"type":21},308,[114],"Acute respiratory distress syndrome (ARDS) is a common clinical syndrome in the ICU characterized by extremely high mortality and complex pathogenesis.At present, research on individualized treatment, phenotypic differences, and therapeutic efficacy in ARDS has become a hotspot.As characterized by syndrome differentiation, traditional Chinese medicine (TCM) treatment emphasizes interindividual heterogeneity and personalized management, which is expected to serve as a breakthrough in multi-target immune regulation for ARDS. The primary objective of the study is to investigate the effect of Xuanbai Shengmai Decoction on the prognosis of patients with ARDS in a prospective randomized controlled trial. The secondary objective is to evaluate the safety of Xuanbai Shengmai Decoction in the treatment of patients with ARDS.",[117],[117,140,141],"Traditional Chinese Medicine","Xuanbai Shengmai Decoction","2026-06-03",{"date":144,"type":30},"2026-06-05",{"date":146,"type":21},"2026-08-20",{"date":148,"type":21},"2027-12",{"name":36,"class":37},{"id":151,"slug":152,"hasResults":12,"nctId":153,"briefTitle":154,"officialTitle":155,"acronym":4,"eligibilityCriteria":156,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":157,"targetDuration":4,"studyType":84,"phases":159,"briefSummary":160,"conditions":161,"keywords":164,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":166,"lastUpdatePostDateStruct":167,"startDateStruct":169,"completionDateStruct":171,"leadSponsor":173,"locationsCount":4},"100640158","bronchoscopic-airway-clearance-for-improving-lung-aeration-in-mechanically-ventilated-patients-with-atelectasis-100640158","NCT07594379","Bronchoscopic Airway Clearance for Improving Lung Aeration in Mechanically Ventilated Patients With Atelectasis","Effect of Bedside Flexible Bronchoscopy-Guided Airway Clearance on Lung Aeration in Mechanically Ventilated Patients With Atelectasis: A Multicenter Randomized Controlled Trial","Inclusion Criteria:\n\n1. Age 18 years or older\n2. Receiving invasive mechanical ventilation for at least 48 hours\n3. Presence of atelectasis confirmed by chest computed tomography, chest X-ray, or lung ultrasound\n4. High airway secretion burden, defined as requiring airway suctioning at least twice per hour during the previous 8 hours\n5. Written informed consent obtained from the participant or legally authorized representative\n\nExclusion Criteria:\n\n1. Expected duration of artificial airway maintenance less than 5 days\n2. Untreated tension pneumothorax Known or suspected aspiration\n3. Active intrapulmonary hemorrhage\n4. Severe dysfunction of other organs with expected short-term mortality within 7 days or need for palliative care\n5. Any other condition judged by the medical team to make the participant unsuitable for the study\n6. Informed consent not obtained",{"count":158,"type":21},104,[86],"The goal of this clinical trial is to learn whether bedside flexible bronchoscopy-guided airway clearance can improve lung aeration in adult patients who are receiving invasive mechanical ventilation and have atelectasis with a high airway secretion burden.\n\nThe main questions it aims to answer are:\n\nDoes bedside flexible bronchoscopy-guided airway clearance reduce the proportion of nonaerated lung tissue from baseline to day 5? Does this treatment improve other lung aeration measures, respiratory mechanics, arterial blood gas parameters, pulmonary infection score, ventilator-free days, intensive care unit length of stay, and safety outcomes?\n\nResearchers will compare usual airway care plus bedside flexible bronchoscopy-guided airway clearance with usual airway care alone to see if bronchoscopy-guided airway clearance improves lung aeration and clinical outcomes.\n\nParticipants will be randomly assigned to one of two groups. Participants in the usual care group will receive standard airway management, which may include airway suctioning, postural drainage, humidification, chest physiotherapy, and other routine respiratory care. Participants in the bronchoscopy group will receive the same usual care, plus bedside flexible bronchoscopy-guided airway clearance when predefined criteria for high airway secretion burden are met.\n\nParticipants will have clinical assessments during the study, including chest imaging, respiratory mechanics measurements, arterial blood gas tests, pulmonary infection score assessment, and safety monitoring. The main assessment will compare quantitative chest computed tomography findings at baseline and day 5 to evaluate changes in nonaerated lung tissue.",[162,163],"Atelectasis","Mechanical Ventilation",[162,163,165],"Airway Secretion Retention","2026-05-21",{"date":168,"type":30},"2026-05-27",{"date":170,"type":21},"2026-06-01",{"date":172,"type":21},"2028-06-01",{"name":36,"class":37},{"id":175,"slug":176,"hasResults":12,"nctId":177,"briefTitle":178,"officialTitle":179,"acronym":4,"eligibilityCriteria":180,"healthyVolunteers":12,"sex":17,"minAge":181,"maxAge":182,"enrollmentInfo":183,"targetDuration":4,"studyType":84,"phases":185,"briefSummary":186,"conditions":187,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":189,"lastUpdatePostDateStruct":190,"startDateStruct":192,"completionDateStruct":194,"leadSponsor":196,"locationsCount":197},"100592211","effect-of-eit-guided-peep-in-ards-patients-100592211","NCT06990477","Effect of EIT-guided PEEP in ARDS Patients","Effect of EIT-guided PEEP On Clinical Outcomes in ARDS Patients: a Multicenter Randomized Controlled Trial","Inclusion Criteria:\n\n1. Age≥18 years\n2. Moderate-to-severe ARDS, defined by the ARDS Definition Task Force in the Berlin definition (partial pressure of arterial oxygen \\[PaO2\\]:FiO2 ratio ≤200 mmHg with a PEEP ≥5 cmH2O)\n3. Diagnosis of ARDS less than 72 hours\n\nExclusion Criteria:\n\n1. Expected to be mechanically ventilated for less than 48 hours\n2. Severe chronic respiratory diseases requiring long-term home oxygen therapy or noninvasive MV\n3. Undrained pneumothorax or subcutaneous emphysema\n4. Contraindication to the use of EIT (pacemaker, automatic implantable cardioverter defibrillator, and implantable pumps)\n5. Severe neuromuscular disease\n6. Hemodynamic instability\n7. Contraindications to hypercapnia, such as intracranial hypertension or acute coronary syndrome\n8. Severe other organs dysfunction with a low expected survival (7 days) or palliative care\n9. Solid organ or hematologic tumors with the expected survival time less than 30 days\n10. Participating in other clinical trials within 30 days\n11. Pregnancy\n12. Refusal to sign the informed consent","19 Years","90 Years",{"count":184,"type":21},2400,[86],"Acute respiratory syndrome distress (ARDS) is a clinical common syndrome with high mortality. Mechanical ventilation (MV) is the cornerstone of management of ARDS but can lead to ventilator-induced lung injury. Positive end-expiratory pressure (PEEP), as one of main component of MV, has been widely used in the clinical practice. However, the PEEP selection is still a difficult problem for moderate to severe ARDS patients. EIT, an imaging tool evaluating the regional ventilation distribution at the bedside, can achieve the individual PEEP selection for all mechanically ventilated patients. Our previous study found that moderate to severe ARDS patients with higher recruitability could benefit from EIT-guided PEEP. This article compared the effect of PEEP titrated guided by EIT with fraction of inspired oxygen (FiO2)-PEEP table on the clinical outcomes in ARDS patients.",[188],"ARDS (Acute Respiratory Distress Syndrome)","2026-05-19",{"date":191,"type":30},"2026-05-22",{"date":193,"type":21},"2026-05-13",{"date":195,"type":21},"2029-02-20",{"name":36,"class":37},3,{"id":199,"slug":200,"hasResults":12,"nctId":201,"briefTitle":202,"officialTitle":202,"acronym":4,"eligibilityCriteria":203,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":204,"targetDuration":4,"studyType":84,"phases":206,"briefSummary":207,"conditions":208,"keywords":212,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":216,"lastUpdatePostDateStruct":217,"startDateStruct":218,"completionDateStruct":220,"leadSponsor":222,"locationsCount":38},"100640506","phase-3-effect-of-remimazolam-sedation-on-outcomes-of-mechanically-ventilated-patients-in-the-icu-100640506","NCT07596589","Effect of Remimazolam Sedation on Outcomes of Mechanically Ventilated Patients in the ICU","Inclusion Criteria:\n\n* Age ≥ 18 years;\n* Endotracheal intubation and mechanical ventilation for 24-96 hours before enrollment Expected need for continued invasive ventilation and sedation for at least 24 hours;\n* Target sedation depth on the Richmond Agitation-Sedation Scale (RASS) between 0 and -3;\n* Informed consent obtained from the patient's family\n\nExclusion Criteria:\n\n* Body mass index (BMI) \\> 30 kg\u002Fm²\n* Severe central nervous system disease (e.g., acute stroke, uncontrolled seizures, or severe dementia) or any other condition that precludes RASS assessment\n* Mean arterial pressure (MAP) \\\u003C 55 mmHg despite intravenous fluid resuscitation and vasopressors\n* Heart rate \\\u003C 50 beats per minute, or second-degree or third-degree atrioventricular block in the absence of a pacemaker\n* Acute myocardial infarction or severe heart failure (New York Heart Association \\[NYHA\\] class IV)\n* Left ventricular ejection fraction \\\u003C 30%\n* Any contraindication or allergy to benzodiazepines\n* Substance dependence, alcohol abuse, or psychiatric\u002Fpsychological disorders. Alcohol abuse was defined as regular consumption of \\> 14 drinks per week (1 drink = 150 mL wine, 360 mL beer, or 45 mL liquor)\n* Acute hepatitis or severe hepatic dysfunction (Child-Pugh class C)\n* Chronic kidney disease with a glomerular filtration rate (GFR) \\\u003C 60 mL\u002Fmin\u002F1.73 m²\n* Neuromuscular disease\n* Patients on extracorporeal membrane oxygenation (ECMO)\n* Pregnancy or breastfeeding",{"count":205,"type":21},80,[114],"The goal of this clinical trial is to evaluate the effect of remimazolam sedation on outcomes of mechanically ventilated ICU patients through a single-center, prospective, randomized controlled, pilot study.",[209,210,211],"Remimazolam Besylate","Mechanically Ventilated ICU Patients","Sedation",[213,214,215],"remimazolam","sedation","ICU","2026-05-18",{"date":189,"type":30},{"date":219,"type":30},"2025-04-01",{"date":221,"type":21},"2027-01-31",{"name":36,"class":37},{"id":224,"slug":225,"hasResults":12,"nctId":226,"briefTitle":227,"officialTitle":228,"acronym":4,"eligibilityCriteria":229,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":230,"targetDuration":4,"studyType":84,"phases":232,"briefSummary":233,"conditions":234,"keywords":237,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":244,"lastUpdatePostDateStruct":245,"startDateStruct":246,"completionDateStruct":248,"leadSponsor":250,"locationsCount":4},"100637731","phenotype-guided-weaning-in-mechanically-ventilated-patients-with-chronic-comorbidities-100637731","NCT07594418","Phenotype-Guided Weaning in Mechanically Ventilated Patients With Chronic Comorbidities","Effect of a Phenotype-Guided Precision Intervention Strategy on 28-Day Ventilator-Free Days in Mechanically Ventilated Patients With Chronic Comorbidities: A Multicenter Open-Label Randomized Controlled Trial","Inclusion Criteria:\n\n1. Age 18 years or older.\n2. Presence of at least one chronic cardiovascular, cerebrovascular, or respiratory comorbidity. Cardiovascular and cerebrovascular comorbidities include stroke, hypertension, ischemic heart disease, valvular heart disease, heart failure, pulmonary heart disease, cardiomyopathy, and arrhythmia. Respiratory comorbidities include chronic obstructive pulmonary disease, asthma, bronchitis, emphysema, interstitial lung disease, and pneumoconiosis. These conditions will be identified according to the International Classification of Diseases 11th Revision diagnosis codes.\n3. Receiving invasive mechanical ventilation for at least 24 hours and expected to require mechanical ventilation for at least 72 hours.\n4. Not receiving neuromuscular blocking agents and having a Richmond Agitation-Sedation Scale score of -3 or higher.\n5. PaO2\u002FFiO2 of 150 mmHg or higher.\n\nExclusion Criteria:\n\n1. Severe neuromuscular disease, such as Guillain-Barre syndrome, myasthenia gravis, amyotrophic lateral sclerosis, multiple sclerosis, or high spinal cord injury.\n2. Severe dysfunction of other organs with expected death in the short term.\n3. Severe end-stage irreversible respiratory, cardiac, neurological, or malignant disease, or receiving palliative care.\n4. Pregnancy.\n5. Participation in another clinical study.\n6. Written informed consent not provided.",{"count":231,"type":21},1380,[86],"The goal of this clinical trial is to learn whether a phenotype-guided weaning strategy can help adults with chronic comorbidities be liberated from invasive mechanical ventilation earlier. It will also learn about the safety of this strategy.\n\nThe main questions it aims to answer are:\n\n* Does the phenotype-guided weaning strategy increase the number of ventilator-free days within 28 days after enrollment?\n* Does the strategy improve the process and success of ventilator liberation?\n* What safety events occur when this strategy is used?\n\nResearchers will compare the phenotype-guided weaning strategy with standard care in mechanically ventilated patients with chronic cardiovascular, cerebrovascular, or respiratory comorbidities.\n\nIn the intervention period, participants will receive a protocolized ventilator weaning pathway. This pathway includes assisted ventilation transition, daily weaning readiness screening, a 0 cmH2O continuous positive airway pressure test, spontaneous breathing trial, extubation assessment, and post-extubation respiratory support when appropriate.\n\nThe phenotype-guided part of the strategy is mainly used for participants who fail a spontaneous breathing trial or have difficult weaning. These participants will undergo structured ABCDE screening to identify the main phenotype or mechanism of weaning failure:\n\n* A: airway or lung dysfunction\n* B: brain dysfunction, including delirium, anxiety, agitation, or impaired consciousness\n* C: cardiac dysfunction\n* D: diaphragm or respiratory muscle dysfunction\n* E: endocrine, metabolic, or nutritional problems\n\nBased on the identified phenotype, clinicians will provide targeted assessment and treatment. Participants will be followed for ventilator-free days through day 28 and for clinical outcomes through day 90.",[235,236],"Mechanical Ventilation Weaning","Chronic Disease",[238,239,240,241,242,243],"Phenotype-Guided Weaning","Ventilator Liberation","Ventilator-Free Days","Chronic Comorbidities","Spontaneous Breathing Trial","ABCDE Screening","2026-05-17",{"date":189,"type":30},{"date":247,"type":21},"2026-09",{"date":249,"type":21},"2027-11",{"name":36,"class":37},{"id":252,"slug":253,"hasResults":12,"nctId":254,"briefTitle":255,"officialTitle":256,"acronym":257,"eligibilityCriteria":258,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":259,"targetDuration":4,"studyType":84,"phases":261,"briefSummary":262,"conditions":263,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":265,"lastUpdatePostDateStruct":266,"startDateStruct":268,"completionDateStruct":270,"leadSponsor":272,"locationsCount":38},"100632886","effect-of-early-transition-to-assisted-ventilation-on-28-day-successful-extubation-in-critically-ill-patients-100632886","NCT07519512","Effect of Early Transition to Assisted Ventilation on 28-day Successful Extubation in Critically Ill Patients","Effect of Early Transition to Assisted Ventilation on 28-day Successful Extubation in Critically Ill Patients: A Multicenter Open-label Randomized Controlled Trial (EARLY-VENT)","EARLY-VENT","Inclusion Criteria:\n\n* Age ≥ 18 years.\n* Expected ICU stay and mechanical ventilation (MV) ≥ 48 hours.\n* Currently receiving controlled ventilation mode\n* No neuromuscular blocking agents in use, and sedation level RASS ≥ -3.\n* P\u002FF ≥ 150 mmHg.\n\nExclusion Criteria:\n\n* Severe end-stage irreversible respiratory, cardiac, or neurologic disease that may lead to long-term\u002Fchronic ventilator dependence or inability to wean from MV (e.g., interstitial lung disease\u002Fpulmonary fibrosis, cardiomyopathy, valvular disease, severe traumatic brain injury, Guillain-Barré syndrome, amyotrophic lateral sclerosis, multiple sclerosis, high cervical spinal cord injury, or other restrictive diseases).\n* Expected death or transfer out of the ICU within 48 hours.\n* Hemodynamic instability judged by the treating clinician.\n* Pregnancy.\n* Currently participating in other clinical studies related to mechanical ventilation.\n* Any other condition considered unsuitable for participation by the investigator.\n\nWritten informed consent not obtained.",{"count":260,"type":21},1600,[86],"EARLY-VENT is a multicenter, open-label, three-period cluster-randomized crossover trial designed to evaluate whether early transition from controlled to assisted ventilation improves outcomes in critically ill patients. The study will enroll approximately 1,600 adult patients across 10 ICUs who are expected to require mechanical ventilation for at least 48 hours and meet specific stability criteria (e.g., hemodynamically stable, light sedation). Participating centers will alternate between an experimental strategy, where patients transition to an assisted mode (preferably Pressure Support Ventilation) within 6 hours of eligibility, and a control strategy based on standard care practices. The primary endpoint is the rate of successful extubation at day 28, aiming to demonstrate that transition from controlled to assisted ventilation can reduce ventilation duration and improve prognosis compared to delayed transition.",[264],"Mechanical Ventilator Care","2026-04-20",{"date":267,"type":30},"2026-04-23",{"date":269,"type":21},"2026-08-01",{"date":271,"type":21},"2030-12-31",{"name":36,"class":37},{"id":274,"slug":275,"hasResults":12,"nctId":276,"briefTitle":277,"officialTitle":277,"acronym":4,"eligibilityCriteria":278,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":279,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":281,"conditions":282,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":283,"lastUpdatePostDateStruct":284,"startDateStruct":286,"completionDateStruct":288,"leadSponsor":290,"locationsCount":4},"100630165","a-retrospective-clinical-study-of-metabolic-status-and-response-to-nutritional-therapy-in-patients-with-mechanical-ventilation-100630165","NCT07484126","A Retrospective Clinical Study of Metabolic Status and Response to Nutritional Therapy in Patients With Mechanical Ventilation","Inclusion Criteria:\n\n* age ≥18 years old;\n* ICU admission ≥72 hours with invasive mechanical ventilation ≥24 hours;\n* start nutrition therapy within 72 hours after ICU admission and receive enteral or parenteral nutrition support for ≥3 days;\n* Relatively complete nutritional intervention records and nutrition-related biomarkers test results on the 1st, 3rd, and 7th (±1) days of ICU admission;\n\nExclusion Criteria:\n\n* women of childbearing age who have a positive pregnancy test, are pregnant or lactating;\n* chronic diseases with serious organ function damage or serious complications;\n\n  1. Kidney: chronic kidney disease stage 4 or 5;\n  2. Liver: previous history of liver failure, hepatic encephalopathy, or hepatic coma, gastrointestinal bleeding due to portal hypertension or Child-Pugh score ≥10 in recent years;\n* advanced malignant tumor, or chemotherapy or immunotherapy received within one month before admission;\n* severe immunodeficiency or current use of potent immunosuppressive agents, agranulocytosis (N\\\u003C0.5×10\\^9\u002FL), active hematologic malignancies or HIV stage III infection; Patients who were treated with immune-inducing drugs, such as antithymocyte globulin (ATG), antilymphocyte globulin (ALG), interleukin-2 receptor a chain antibody (IL-2RA), interleukin-6 receptor A antibody (IL-6RA); glucocorticoid therapy was continued for nearly 2 weeks, with a daily dose exceeding the hydrocortisone equivalent of 200mg;\n* critical illness, death in ICU within 1 week or palliative care only because death outcome was inevitable;\n* combined with severe or more severe burns: more than 30% of total body surface area burned or more than 10% of third-degree burn area; Or the total area is less than 30%, but the whole body condition is severe, or there are shock, combined injury, and respiratory tract burn.",{"count":280,"type":21},2000,"This study used a retrospective cohort study based on Multi-time longitudinal monitoring data were used to analyze the correlation mechanism between the dynamic evolution characteristics of nutrition-related biochemical indicators and individualized nutritional intervention in patients with mechanical ventilation. The inflammation-nutrition interaction model was constructed to correct the interference effect of inflammatory microenvironment on nutritional status assessment, so as to provide a basis for further achieving precision nutritional support.",[163],"2026-03-17",{"date":285,"type":30},"2026-03-19",{"date":287,"type":21},"2026-04",{"date":289,"type":21},"2026-08",{"name":36,"class":37},{"id":292,"slug":293,"hasResults":12,"nctId":294,"briefTitle":295,"officialTitle":296,"acronym":4,"eligibilityCriteria":297,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":47,"enrollmentInfo":298,"targetDuration":4,"studyType":84,"phases":300,"briefSummary":301,"conditions":302,"keywords":304,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":307,"lastUpdatePostDateStruct":308,"startDateStruct":310,"completionDateStruct":312,"leadSponsor":314,"locationsCount":38},"100620816","enteral-nutrition-delivery-in-prone-position-ventilated-patients-with-moderate-to-severe-ards-100620816","NCT07362537","Enteral Nutrition Delivery in Prone Position Ventilated Patients With Moderate to Severe ARDS","Enteral Nutrition Delivery in Prone Position Ventilated Patients With Moderate to Severe Acute Respiratory Distress Syndrome: a Randomized Controlled Trial","Inclusion Criteria:\n\n* ARDS patients who meet the Berlin criteria for ARDS and have a P\u002FF ratio ≤ 200mmHg.\n* Patients receiving invasive mechanical ventilation and clinically judged to require prone ventilation, with an anticipated daily prone positioning time of ≥12 hours and a duration of prone ventilation therapy of ≥3 days.\n* Patients planned to receive enteral nutrition.\n* Age ≥18 and ≤85 years.\n* Consent to sign an informed consent form.\n\nExclusion Criteria:\n\n* Contraindications to enteral nutrition, such as severe intestinal ischemia, active upper gastrointestinal bleeding, high-output intestinal fistula without a distal feeding route, abdominal compartment syndrome, severe diarrhea, intestinal obstruction, etc.\n* Presence of shock with hemodynamic instability (norepinephrine or equivalent vasopressor dosage ≥0.5ug\u002Fkg.min) or tissue hypoperfusion (lactate \\>3mmol\u002FL).\n* Life-threatening hypoxemia, hypercapnia, and acidosis.\n* Inability to tolerate prone ventilation (e.g., pregnant women, limb contractures, recent fractures, recent thoracic or abdominal surgery, pacemaker insertion within 48 hours, spinal instability, pelvic fractures, facial fractures, anticipated difficult airway).\n* Conditions preventing nasogastric or nasojejunal tube placement (e.g., esophageal rupture, severe esophageal varices).\n* Anticipated inability to start enteral nutrition within 48 hours.\n* Use of prokinetic agents within 48 hours prior to starting enteral nutrition.\n* Enteral nutrition via gastrostomy or jejunostomy.\n* Expected ICU stay or survival time less than 3 days.\n* Patients refusing further resuscitative treatment.\n* Pregnant or breastfeeding women.\n* Patients already enrolled in other interventional clinical studies or deemed unsuitable for the study by the clinician.",{"count":299,"type":21},40,[86],"This pilot study is aimed to compare and assess the impact, safety, and practical utility of gastric versus postpyloric feeding in moderate to severe ARDS patients with prone position ventilation. Patients included will be randomly assigned to receive enteral nutrition either through a nasogastric tube or a nasojejunal tube. The primary endpoint is the achievement of enteral nutrition goals. Secondary endpoints include the incidence of hospital-acquired infections, the number of ventilator-free days within 28 days, ICU length of stay, ICU mortality, 28-day mortality, 60-day mortality rates, the incidence of enteral nutrition intolerance, and the rate of enteral nutrition intake.",[303],"ARDS",[303,305,306],"prone position ventilation","enteral nutrition","2026-01-16",{"date":309,"type":30},"2026-01-23",{"date":311,"type":21},"2026-01-20",{"date":313,"type":21},"2026-10-31",{"name":36,"class":37},{"id":316,"slug":317,"hasResults":12,"nctId":318,"briefTitle":319,"officialTitle":320,"acronym":4,"eligibilityCriteria":321,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":322,"targetDuration":4,"studyType":84,"phases":323,"briefSummary":324,"conditions":325,"keywords":327,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":333,"lastUpdatePostDateStruct":334,"startDateStruct":336,"completionDateStruct":338,"leadSponsor":340,"locationsCount":4},"100618907","liposomal-amphotericin-b-in-invasive-aspergillosis-with-hepatic-dysfunction-100618907","NCT07337720","Liposomal Amphotericin B in Invasive Aspergillosis With Hepatic Dysfunction","Liposomal Amphotericin B in Patients With Invasive Aspergillosis and Hepatic Dysfunction: A Prospective Study","Inclusion Criteria\n\nPatients must meet all of the following criteria to be eligible for enrollment:\n\n1. Willing to participate in the study and able to provide written informed consent;\n2. Hospitalized patients admitted to the intensive care unit (ICU);\n3. Age ≥ 18 years, with no restriction on sex;\n4. Proven or probable invasive aspergillosis (IA), defined as follows:\n\nProven IA\n\nProven IA is diagnosed if at least one of the following criteria is met:\n\n1. Histopathological or cytopathological evidence of invasive Aspergillus spp. hyphae in tissue specimens obtained from a sterile site or the lung (e.g., biopsy or needle aspiration), with confirmation by culture or polymerase chain reaction (PCR);\n2. Isolation of Aspergillus spp. by culture from a specimen obtained from a sterile site (e.g., biopsy or needle aspiration), with the lesion consistent with an infectious process.\n\nProbable IA\n\nProbable IA requires the presence of all of the following criteria:\n\n1. At least one host factor (e.g., COVID-19, influenza, solid malignancy, HIV infection with CD4 \\\u003C200 cells\u002FµL, decompensated liver cirrhosis, or moderate to severe chronic obstructive pulmonary disease \\[COPD\\]);\n2. At least one compatible clinical feature (e.g., fever ≥38.3 °C lasting ≥3 days, pleuritic chest pain, dyspnea, hemoptysis, or worsening respiratory failure despite appropriate antibacterial therapy);\n3. At least one compatible radiological finding (e.g., newly developed pulmonary infiltrates on chest computed tomography, or cavitary lesions not explained by other causes);\n4. At least one mycological criterion (e.g., positive culture for Aspergillus spp. from bronchoalveolar lavage fluid \\[BALF\\], serum galactomannan \\>0.5 optical density index \\[ODI\\], or BALF galactomannan ≥1.0 ODI).\n5. Concomitant hepatic dysfunction meeting at least one of the following conditions:\n\n   * Aminotransferase levels \\>3 times the upper limit of normal (ULN) and \\\u003C10 times ULN;\n   * Child-Pugh class A or B;\n6. Expected to receive antifungal therapy for ≥5 days.\n\nExclusion Criteria\n\nPatients meeting any of the following criteria will be excluded:\n\n1. Pregnant or breastfeeding women;\n2. Known allergy or hypersensitivity to amphotericin B or any of its formulations;\n3. Previous treatment with extracorporeal membrane oxygenation (ECMO);\n4. Expected life expectancy \\\u003C48 hours;\n5. Patients who, at the time of enrollment, are confirmed to require antifungal agents other than those specified in the study protocol;\n6. Presence of any of the following severe comorbid conditions that may interfere with assessment of study efficacy or safety:\n\n   * Acute liver failure or acute decompensation of chronic liver failure;\n   * Known or suspected active pulmonary tuberculosis, cystic fibrosis, lung abscess, empyema, or obstructive pneumonia;\n7. Severe renal impairment, defined as any of the following:\n\n   * Creatinine clearance (CrCL) \\\u003C16 mL\u002Fmin at enrollment;\n   * Requirement for hemodialysis, peritoneal dialysis, or other renal replacement therapy at enrollment;\n8. Participation in another clinical trial within 3 months prior to enrollment;\n9. Previous enrollment in this study;\n10. Any condition that may affect study compliance or outcome assessment (e.g., planned major surgery, or inability to comply with the study protocol due to disease severity or poor adherence);\n11. Any other condition deemed by the investigator to make the patient unsuitable for participation.",{"count":299,"type":21},[86],"Liposomal amphotericin B is an antifungal agent commonly used to treat invasive aspergillosis, a severe fungal infection associated with high mortality in critically ill patients. However, evidence regarding its safety and effectiveness in patients with hepatic dysfunction is limited.\n\nIn China, patients diagnosed with invasive aspergillosis complicated by hepatic dysfunction will be recruited from multiple centers. Eligible patients will receive treatment with liposomal amphotericin B according to the study protocol. The safety and effectiveness of liposomal amphotericin B in this patient population will be evaluated.\n\nThis study aims to provide clinical evidence to support antifungal treatment decisions for patients with invasive aspergillosis and impaired liver function.",[326],"Aspergillosis Invasive",[328,329,330,331,332],"Invasive Aspergillosis","Liposomal Amphotericin B","Hepatic Dysfunction","Critically Ill Patients","Antifungal Therapy","2026-01-04",{"date":335,"type":30},"2026-01-13",{"date":337,"type":21},"2025-12-20",{"date":339,"type":21},"2027-03-20",{"name":36,"class":37},{"id":342,"slug":4,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":14,"acronym":15,"eligibilityCriteria":343,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":344,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":345,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":346,"startDateStruct":348,"completionDateStruct":349,"leadSponsor":350,"locationsCount":38},"100615215","Inclusion Criteria:\n\n1. Age ≥ 18 years.\n2. ARDS requiring invasive mechanical ventilation, diagnosed according to the 2023 Global definition.\n3. Onset of ARDS within 72 hours.\n\nExclusion Criteria:\n\n1. Refusal of informed consent by the patient's legally authorized representative.\n2. Patients expected to die within 24 hours",{"count":20,"type":21},[25],{"date":347,"type":30},"2026-01-02",{"date":32,"type":30},{"date":34,"type":21},{"name":36,"class":37},{"id":352,"slug":353,"hasResults":12,"nctId":354,"briefTitle":355,"officialTitle":355,"acronym":356,"eligibilityCriteria":357,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":358,"targetDuration":360,"studyType":22,"phases":4,"briefSummary":361,"conditions":362,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":363,"startDateStruct":364,"completionDateStruct":366,"leadSponsor":368,"locationsCount":38},"100614845","practices-of-prone-positioning-ventilation-in-patients-with-moderate-to-severe-ards-in-intensive-care-units-a-registry-based-observational-study-100614845","NCT07284888","Practices of Prone Positioning Ventilation in Patients With Moderate-to-Severe ARDS in Intensive Care Units: A Registry-Based Observational Study","PPV SAFE","Inclusion Criteria:\n\n1.Age ≥ 18 years 2. Moderate-to-severe ARDS requiring invasive mechanical ventilation, defined as:\n\n1. PaO₂\u002FFiO₂ ≤ 150 mm Hg,\n2. PEEP ≥ 5 cm H₂O,\n3. ARDS diagnosed according to the 2023 Global Definition.\n\nExclusion Criteria:\n\n1.Refusal of informed consent by the patient's legally authorized representative",{"count":359,"type":21},1000,"60 Days","Acute respiratory distress syndrome (ARDS) is a major cause of mortality in intensive care units. Prone position ventilation (PPV) is an important component of ARDS management and has been shown to reduce mortality in patients with moderate-to-severe ARDS. However, substantial heterogeneity exists in treatment response to PPV. Previous studies suggest that lung morphology-focal versus non-focal patterns based on chest CT-may influence responses to ventilatory strategies, but whether lung morphology modifies the effect of PPV remains unclear. In addition, the benefits and safety of PPV in patients with acute brain injury (ABI) complicated by ARDS are uncertain. Although PPV improves oxygenation, it may impair cerebral venous drainage and increase intracranial pressure, raising concerns about its use in ABI patients. Evidence from randomized trials in this population is limited and excludes patients with more severe hypoxemia or elevated intracranial pressure.\n\nFurthermore, the optimal duration and termination criteria for PPV are not well established. While PPV improves alveolar recruitment and reduces ventilator-induced lung injury, prolonged PPV may lead to excessive sedation exposure and PPV-related complications. Identifying the appropriate timing to discontinue PPV may help balance clinical benefits and potential harms.This study is a prospective, multicenter registry enrolling patients with moderate-to-severe ARDS. The objectives are: (1) To determine whether lung morphology can guide individualized PPV strategies; (2) To evaluate the effectiveness and safety of PPV in patients with ARDS complicated by acute brain injury; (3) To investigate the optimal timing for termination of PPV through target trial emulation methods.In addition to these core objectives, the study will include other exploratory aims.",[25],{"date":347,"type":30},{"date":365,"type":21},"2026-01-01",{"date":367,"type":21},"2029-01-31",{"name":36,"class":37},{"id":370,"slug":371,"hasResults":12,"nctId":372,"briefTitle":373,"officialTitle":374,"acronym":4,"eligibilityCriteria":375,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":376,"enrollmentInfo":377,"targetDuration":50,"studyType":22,"phases":4,"briefSummary":378,"conditions":379,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":382,"lastUpdatePostDateStruct":383,"startDateStruct":385,"completionDateStruct":386,"leadSponsor":388,"locationsCount":38},"100618103","cyclic-on-off-switching-of-pulmonary-blood-flow-in-moderate-to-severe-ards-100618103","NCT07327268","Cyclic On-off Switching of Pulmonary Blood Flow in Moderate to Severe ARDS","Cyclic On-off Switching of Pulmonary Blood Flow in Moderate to Severe ARDS Patients With Mechanical Ventilation","Inclusion Criteria:\n\n1. Adult patients with mechanical ventilation\n2. diagnosis of moderate to severe ARDS no more than 72 hours\n\nExclusion Criteria:\n\n1. Chronic respiratory diseases that required long-term oxygen therapy, such as pulmonary fibrosis or chronical obstructive pulmonary disease\n2. Contraindications to EIT (e.g., active implantable device, chest malformation, unstable spinal injuries or fractures, and open chest wounds)\n3. Undrained pneumothorax or pneumomediastinum,\n4. Hemodynamic instability\n5. Pregnancy\n6. Refusal by family or the attending physician to participate in the study.","75 Years",{"count":299,"type":21},"Although the theoretical model of \"cyclic on-off switching of pulmonary blood flow\" provides a crucial perspective for understanding VILI, its clinical validation and real-time intervention face significant obstacles. The fundamental reason lies in the lack of pulmonary microcirculation monitoring technology capable of bedside, non-invasive, continuous operation with sufficient spatiotemporal resolution. Nowadays, a novel 3D-EIT can perform real-time and non-invasive assessment of the distribution of pulmonary blood flow. However, if 3D-EIT can help to identify \"cyclic on-off switching of pulmonary blood flow\" is still unclear.",[188,380,381],"Electrical Impedance Tomography (EIT)","Pulmonary Perfusion","2025-12-25",{"date":384,"type":30},"2026-01-08",{"date":365,"type":21},{"date":387,"type":21},"2026-08-31",{"name":36,"class":37},{"id":390,"slug":391,"hasResults":12,"nctId":392,"briefTitle":393,"officialTitle":394,"acronym":4,"eligibilityCriteria":395,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":396,"targetDuration":4,"studyType":84,"phases":398,"briefSummary":399,"conditions":400,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":402,"lastUpdatePostDateStruct":403,"startDateStruct":405,"completionDateStruct":407,"leadSponsor":408,"locationsCount":4},"100611956","the-effects-of-different-non-invasive-respiratory-support-100611956","NCT07247318","The Effects of Different Non-invasive Respiratory Support","The Physiological Effects of Different Non-invasive Respiratory Support in Patients With Acute Hypoxemic Respiratory","Inclusion Criteria:\n\n* Age ≥ 18 years;\n* PaO₂\u002FFiO₂ ≤ 300 mmHg or SpO₂\u002FFiO₂ ≤ 315 (with SpO₂ ≤ 97%);\n* Requiring one of the following respiratory supports:\n\n  1. Noninvasive positive pressure ventilation with PEEP ≥ 5 cmH₂O, or\n  2. High-flow nasal oxygen therapy with a flow rate ≥ 30 L\u002Fmin, or\n  3. Conventional oxygen therapy with an oxygen flow ≥ 10 L\u002Fmin, where FiO₂ is calculated using the formula: FiO₂ = 0.21 + (oxygen flow rate × 0.03).\n\nExclusion Criteria:\n\n* Received CPAP or NIV for more than 24 hours prior to screening.\n* Received invasive mechanical ventilation during the current hospitalization.\n* Presence of chronic underlying pulmonary disease, or PaCO₂ ≥ 45 mmHg.\n* Presence of cardiogenic pulmonary edema.\n* Hemodynamic instability, defined as systolic blood pressure \\\u003C 90 mmHg or norepinephrine-equivalent dose \\> 0.3 µg\u002Fkg\u002Fmin.\n* Impaired consciousness (GCS ≤ 12).\n* Patients requiring urgent intubation, including those with respiratory or cardiac arrest, apnea with loss of consciousness or gasping, or severe hypoxemia (defined as SpO₂ \\\u003C 90% despite 100% oxygen).\n* Contraindications to NIV: cardiac or respiratory arrest, coma, untreated pneumothorax, uncontrollable vomiting, upper airway obstruction, hematemesis or severe facial trauma, or thoracic\u002Fabdominal surgery within the past 7 days.\n* Contraindications to EIT: implanted cardiac pacemaker, unstable spinal injury or fracture, or open chest trauma.\n* Refusal of endotracheal intubation.\n* Pregnancy.",{"count":397,"type":21},60,[86],"Patients with acute hypoxemic respiratory failure (AHRF) typically present with pathophysiological alterations characterized by the coexistence of respiratory dysfunction and hypoxemia. Respiratory dysfunction leads to dyspnea, increased work of breathing, use of accessory respiratory muscles, and hypercapnia, while gas exchange impairment results in hypoxemia. Studies have shown that hypercapnia, acidosis, and hypoxemia can all enhance inspiratory effort, which further increases negative intrathoracic pressure. In these patients, regional differences in airway resistance and lung compliance are often present, causing redistribution of air within the lungs. This redistribution manifests as gas movement from non-dependent to dependent regions, known as \"pendelluft,\" which amplifies regional alveolar strain and ventilation heterogeneity. This phenomenon becomes more pronounced during noninvasive respiratory support when spontaneous breathing is preserved.\n\nNoninvasive respiratory support strategies mainly include high-flow nasal oxygen (HFNO), noninvasive positive pressure ventilation (NIV), and continuous positive airway pressure (CPAP). HFNO delivers high-flow gas through nasal cannulas, generating a certain level of positive end-expiratory pressure (PEEP) and flushing out anatomical dead space to improve gas exchange, thereby reducing inspiratory effort, lowering the work of breathing, and enhancing oxygenation. NIV, typically using pressure support ventilation (NIV-PSV), is a patient-triggered, pressure-targeted mode that provides inspiratory positive pressure above PEEP. By augmenting tidal volume and reducing inspiratory effort, NIV improves gas exchange; however, leaks may limit the effective delivery of PEEP, and full inspiratory synchronization can increase transpulmonary driving pressure and tidal volume. CPAP, by contrast, delivers a constant positive pressure during both inspiration and expiration. Compared with HFNO, CPAP generates higher PEEP, which facilitates alveolar recruitment and more effectively improves oxygenation. Relative to NIV, CPAP may reduce transpulmonary driving pressure and tidal volume.\n\nDifferent noninvasive respiratory support strategies exert varying effects on respiratory drive and regional lung strain, leading to differences in the occurrence and magnitude of pendelluft. Physiological studies have suggested that CPAP may offer greater benefits in improving oxygenation and reducing inspiratory effort; however, whether it can mitigate the occurrence and extent of pendelluft remains uncertain. Therefore, this study was conducted to visualize and quantitatively assess pendelluft in real time using electrical impedance tomography (EIT), aiming to verify whether CPAP has a superior effect in reducing pendelluft in patients with AHRF.",[401],"Acute Respiratory Failure (ARF)","2025-11-20",{"date":404,"type":30},"2025-11-25",{"date":406,"type":21},"2025-11-30",{"date":34,"type":21},{"name":36,"class":37},{"id":410,"slug":411,"hasResults":12,"nctId":412,"briefTitle":413,"officialTitle":414,"acronym":4,"eligibilityCriteria":415,"healthyVolunteers":12,"sex":17,"minAge":181,"maxAge":4,"enrollmentInfo":416,"targetDuration":50,"studyType":22,"phases":4,"briefSummary":417,"conditions":418,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":402,"lastUpdatePostDateStruct":419,"startDateStruct":421,"completionDateStruct":422,"leadSponsor":423,"locationsCount":38},"100586754","the-physiological-effect-of-rcexp-on-ventilationperfusion-distribution-100586754","NCT06919484","The Physiological Effect of RCexp on Ventilation\u002FPerfusion Distribution","The Physiological Effect of RCexp on Ventilation\u002FPerfusion Distribution in Patients With ARDS","Inclusion Criteria:\n\nadult patients with ARDS receiving mechanical ventilation no more than 72 hours\n\nExclusion Criteria:\n\n1. age \\\u003C18 years old\n2. patient undergoing legal protection\n3. contra-indications to EIT (e. g. severe chest trauma or wounds)\n4. pneumothorax\n5. patient undergoing ECMO\n6. pregnancy",{"count":397,"type":21},"With the exception of setting the positive end-expiratory pressure (PEEP), the expiratory phase is commonly overlooked during MV. The expiratory time constant (RCexp) plays an important role in understanding the mechanical properties of the respiratory system in patients receiving mechanical ventilation. However, it is unclear that the effect of expiratory time constant on the ventilation and perfusion distribution.",[25,163],{"date":420,"type":30},"2025-11-26",{"date":406,"type":21},{"date":34,"type":21},{"name":36,"class":37},{"id":425,"slug":426,"hasResults":12,"nctId":427,"briefTitle":428,"officialTitle":429,"acronym":4,"eligibilityCriteria":430,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":431,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":433,"conditions":434,"keywords":437,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":441,"lastUpdatePostDateStruct":442,"startDateStruct":444,"completionDateStruct":446,"leadSponsor":448,"locationsCount":449},"100557745","weaning-from-mechanical-ventilation-in-patients-with-acute-brain-injury-100557745","NCT06542107","Weaning From Mechanical Ventilation in Patients With Acute Brain Injury","Prediction of Weaning for Patients With Acute Brain Injury Undergoing Mechanical Ventilation","Inclusion Criteria:\n\n* acute brain injury\n* age \\>=18 years\n* invasive mechanical ventilation for at least 24 hours\n\nExclusion Criteria:\n\n* tracheostomized before ICU admission\n* pregnant or lactation\n* with cervical spinal cord injury\n* decision to receive palliative care within 24 hours of ICU admission",{"count":432,"type":21},406,"Acute brain injury (ABI) patients frequently necessate intubation and invasive mechanical ventilation (IMV). While some ABI patients are capable of breathing spontaneously, which is one of the main criteria of extubation and weaning. However, the rate of extubation failure was significantly higher in ABI patients compared with non-neurological critical care patients. In patients who have failed one or several trials of extubation, tracheostomy is recommend according to the latest ESICM consensus. Tracheostomy can enhance comfort, improve pulmonary hygiene and decrease sedation requirement, which could facilitate the liberation from ventilator.\n\nNumerous studies have explored the causes of weaning failure and provide various predictive models in guiding extubation and tracheostomy. Yet, due to limitations of such as small sample size or a lack of external validation, there is paucity of practical weaning algorithm tailored for ABI patients. The liberation from IMV in ABI patients still remains challenging with poor level of evidence in current guidelines or expert consensus.\n\nWe aim to describe the weaning outcomes in ABI patients, and further investigate the potential predictors of weaning success in ABI patients.",[435,436],"Ventilator Lung","Acute Brain Injury",[438,439,440],"mechanical ventilation","acute brain injury","weaning","2025-11-14",{"date":443,"type":30},"2025-11-18",{"date":445,"type":30},"2024-08-06",{"date":447,"type":21},"2025-12-31",{"name":36,"class":37},2,{"id":451,"slug":452,"hasResults":12,"nctId":453,"briefTitle":454,"officialTitle":455,"acronym":4,"eligibilityCriteria":456,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":182,"enrollmentInfo":457,"targetDuration":459,"studyType":22,"phases":4,"briefSummary":460,"conditions":461,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":463,"lastUpdatePostDateStruct":464,"startDateStruct":466,"completionDateStruct":468,"leadSponsor":470,"locationsCount":38},"100600666","or6a2-on-monocytes-and-cardiovascular-outcomes-in-myocardial-ischemia-reperfusion-injury-100600666","NCT07100457","OR6A2 on Monocytes and Cardiovascular Outcomes in Myocardial Ischemia-Reperfusion Injury","Association of OR6A2 Expression on Monocytes With Inflammation and Major Adverse Cardiovascular Events in Myocardial Ischemia-Reperfusion Injury","Inclusion Criteria:\n\n1. Acute myocardial infarction (AMI) patients with angiographically-confirmed coronary artery disease undergoing primary percutaneous coronary intervention (PCI), and subsequently diagnosed with protocol-defined myocardial ischemia-reperfusion injury during the post-PCI period.\n2. Age 18-90 years inclusive.\n\nExclusion Criteria:\n\n1. Active systemic infections.\n2. Advanced heart failure (NYHA class III-IV).\n3. Acute cerebrovascular conditions.\n4. Active myocarditis.\n5. cardiomyopathy.\n6. Refractory ventricular tachycardia\u002Ffibrillation.\n7. Diagnosis\u002Fconcurrent treatment for malignancy within 5 years (except non-melanoma skin cancer\u002Fcarcinoma in situ).\n8. Severe renal insufficiency (estimated glomerular filtration rate \\[eGFR\\] \\\u003C30 mL\u002Fmin\u002F1.73m2 or dialysis dependence).\n9. Child-Pugh class C hepatic dysfunction.",{"count":458,"type":21},200,"44 Months","This study examines how the interaction between octanal (an OR6A2 receptor activator) and OR6A2 expression influences inflammation and clinical outcomes in Myocardial Ischemia-Reperfusion Injury patients. We analyze two key relationships: 1) The octanal-OR6A2 pathway's association with systemic oxidative stress\u002Finflammatory biomarkers, and 2) How OR6A2 expression patterns on monocyte subtypes and plasma octanal levels correlate with major cardiovascular events. Patients undergoing this post-revascularization injury provided blood samples for OR6A2\u002Foctanal\u002Finflammation measurements. IR Injury patients underwent 44-month clinical follow-up. Results may identify biological markers for personalized risk assessment after revascularization therapies. Ethics approval: Zhongda Hospital #2020ZDSYLL051-P01.",[462],"Myocardial Ischemia-Reperfusion Injury","2025-07-30",{"date":465,"type":30},"2025-08-03",{"date":467,"type":30},"2019-09-01",{"date":469,"type":21},"2027-08-30",{"name":36,"class":37},{"id":472,"slug":473,"hasResults":12,"nctId":474,"briefTitle":475,"officialTitle":476,"acronym":477,"eligibilityCriteria":478,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":479,"targetDuration":50,"studyType":22,"phases":4,"briefSummary":481,"conditions":482,"keywords":483,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":486,"lastUpdatePostDateStruct":487,"startDateStruct":489,"completionDateStruct":491,"leadSponsor":493,"locationsCount":38},"100598315","effect-of-xuebijing-injection-on-outcomes-in-sepsis-patients-under-real-world-conditionsexit-sep-real-100598315","NCT07069894","Effect of Xuebijing InjecTion on Outcomes in Sepsis Patients Under Real-World Conditions（EXIT-SEP REAL）","Effect of Xuebijing InjecTion on Outcomes in Sepsis Patients Under Real-World Conditions: A Patient Registry","EXIT-SEP REAL","Inclusion Criteria:\n\n* Hospitalized patients aged ≥18 years\n* Sepsis diagnosis meeting Sepsis-3 criteria\n* Informed consent signed by patient or legally authorized representative\n\nExclusion Criteria:\n\n* Patients with a prior history of sepsis\n* Sepsis diagnosis \\>48 hours prior to enrollment\n* Current participation in clinical trial",{"count":480,"type":21},5400,"Xuebijing injection (XBJ) showed proven efficacy in the EXIT-SEP trial (NCT03238742), lowering 28-day mortality. However, its real-world effectiveness requires validation due to the trial's strict criteria. Broader clinical evaluation is imperative.",[53],[53,484,485],"Xuebijing injection","Intensive Care Unit","2025-07-15",{"date":488,"type":30},"2025-07-17",{"date":490,"type":21},"2025-08-01",{"date":492,"type":21},"2027-09",{"name":36,"class":37},{"id":495,"slug":496,"hasResults":12,"nctId":497,"briefTitle":498,"officialTitle":499,"acronym":500,"eligibilityCriteria":478,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":501,"targetDuration":50,"studyType":22,"phases":4,"briefSummary":503,"conditions":504,"keywords":505,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":508,"lastUpdatePostDateStruct":509,"startDateStruct":510,"completionDateStruct":512,"leadSponsor":514,"locationsCount":38},"100598058","outcomes-of-sepsis-patients-in-china-china-sep-100598058","NCT07066553","Outcomes of Sepsis Patients in China (CHINA-SEP)","Outcomes of Sepsis Patients in China: A Registry","CHINA-SEP",{"count":502,"type":21},5775,"Sepsis poses a significant public health challenge in China. However, longitudinal real-world evidence on guideline adherence and patient outcomes remains scarce. This registry aims to address these gaps by systematically capturing guideline-concordant treatment patterns and associated outcomes in ICU patients diagnosed according to Sepsis-3.0 criteria across diverse settings, thereby generating actionable evidence to improve the quality of sepsis care nationwide.",[53],[506,53,485,507],"China","Outcomes","2025-07-14",{"date":486,"type":30},{"date":511,"type":21},"2025-07-18",{"date":513,"type":21},"2027-08",{"name":36,"class":37},{"id":516,"slug":517,"hasResults":12,"nctId":518,"briefTitle":519,"officialTitle":520,"acronym":4,"eligibilityCriteria":521,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":47,"enrollmentInfo":522,"targetDuration":4,"studyType":84,"phases":524,"briefSummary":525,"conditions":526,"keywords":528,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":533,"lastUpdatePostDateStruct":534,"startDateStruct":536,"completionDateStruct":538,"leadSponsor":539,"locationsCount":540},"100520050","efficacy-and-safety-of-colistimethate-sodium-for-injection-in-the-treatment-of-carbapenem-resistant-enterobacteriaceae-infection-100520050","NCT06051513","Efficacy and Safety of Colistimethate Sodium for Injection in The Treatment of Carbapenem-Resistant Enterobacteriaceae Infection","Colistimethate Sodium for Injection in The Treatment of Carbapenem-Resistant Enterobacteriaceae Infection：a Prospective, Open-label, Randomized Controlled, Multicenter Clinical Trial","Inclusion Criteria:\n\n1. Patients who can provide written informed consent or their informed consent can be provided by legal guardian\n2. Patients who are hospitalized\n3. Adults ≥18 years and ≤85 years of age\n4. Patients suspected of or diagnosed with hospital-acquired pneumonia (HAP, in a patient hospitalised for more than 48 hours or developing within 7 days after discharge from a hospital) or bloodstream infection caused carbapenem-resistant enterobacteriaceae (CRE) based on the culture results of the sample collected 5 days before the randomization or rapid diagnostic detection.\n\n   Rapid testing of respiratory or blood specimens should be used to enable early identification of CRE infection pneumonia. Patients can be randomized based on the results of the rapid test while awaiting results of cultures from the local laboratory. However, if the sample does not grow CRE in the local microbiology laboratory culture, these patients will be withdrawn from the study drug treatment.\n\n   Patients with HAP should fulfil one of the following systemic signs: 1)Fever (temperature \\>38°C) or hypothermia (rectal\u002Fcore temperature \\\u003C35°C);2)White blood cell (WBC) count \\>10,000 cells\u002Fmm3, or WBC count \\\u003C4500 cells\u002Fmm3, or \\>15% band forms and fulfil at least two of the following respiratory signs or symptoms:1)a new onset of cough (or worsening of cough);2)production of purulent sputum or endotracheal secretions;3)auscultatory findings consistent with pneumonia\u002Fpulmonary consolidation (e.g., rales, rhonchi, bronchial breath sounds, dullness to percussion, egophony);4)dyspnoea, tachypnoea or hypoxaemia (O2 saturation \\\u003C90% or pO2 \\\u003C60 mmHg while breathing room air).\n\n   Patients with bloodstream infection should fulfil one of the following criterion:1)fever(≥38 ℃);2)chills;3)hypotension(systolic \\\u003C90 mmHg, requiring vasopressors to maintain mean arterial pressure ≥60 mmHg,decreased by 30mmHg from baseline) ,and isolation of CRE from at least two blood culture collected from two different sites.\n5. Respiratory or blood specimen obtained for culture within 5 days prior to randomization, and after the onset of signs and symptoms of HAP or bloodstream infection (ideally before receipt of any systemic antibiotics).\n6. Patients whose APACHE II score is between 10 and 30.\n\nExclusion Criteria:\n\n1. Patients who received polymyxin for more than 48 hours in the 72 hours prior to randomization.\n2. Patients who received antibiotics more than 24 hours in the 72 hours prior to randomization, and after treatment，conditions of patients improved.\n3. Patient with history of serious allergy, hypersensitivity (eg, anaphylaxis), or any serious reaction to Colistimethate Sodium for Injection or other ingredients of it.\n4. Evidence of active concurrent pneumonia requiring additional antimicrobials treatment caused by Streptococcus pneumoniae，Haemophilus influenzae，Methicillin-resistant staphylococcus aureus，Vancomycin-resistant enterococcus，Mycoplasma pneumonia，Legionella pneumophila, respiratory syncytial virus, influenza virus, parainfluenza virus, Middle East Respiratory Virus, Mycobacteria, Aspergillus, Mucormycosis, Candida,etc. If these organisms are identified but it is deemed by the Investigator that no treatment is warranted and their presence does not significantly change the prognosis of the patient, then the patient may be considered for this study.\n5. Patients who are diagnosed with primary lung cancer (including small cell lung cancer\u002Fnon-small cell lung cancer patients) or other malignancy transferred to the lungs or other known post obstructive pneumonia. Patients who is known or suspected of active tuberculosis, cystic fibrosis, lung abscess, pyothorax or obstructive pneumonia.\n6. Patients with hematological malignancy such as leukemia, lymphoma and multiple myeloma.\n7. Patients with lung\u002Fheart transplantation or stem cell transplantation.\n8. Patient was immunocompromised and at risk of infection by opportunistic pathogens including, but not limited to the following:1) HIV (AIDS or CD4 \\\u003C200). 2) chemoradiotherapy within 3 months prior to randomisation. 3) Immunosuppressive therapy including maintenance corticosteroids (0.5 mg\u002Fkg prednisone per day or other equivalent glucocorticoid). 4) Absolute neutrophil count \\\u003C500\u002Fmm3.\n9. Patients with chronic liver failure with portal hypertension, acute hepatic failure or acute decompensation of chronic hepatic failure.\n10. Patients who participated in other clinical trials within three months.\n11. Patient was pregnant or breastfeeding. If either urine or serum β-hCG test was positive, the patient was excluded.\n12. Patient who have been previously enrolled in this study.\n13. Patients who have condionts that may affect the trial.\n14. Other conditions exist researchers thought are not suitable.",{"count":523,"type":21},404,[86],"Colistin can be used to treat the infection caused by carbapenem-resistant enterobacteriaceae(CRE). In China, patients diagnosed with Hospital-acquired-pneumonia (HAP)or bloodstream infection caused by CRE are recruited, and randomly assigned to two groups, and in one group the patients accept treatment with colistin, however in another group, the patients accept treatment without colistin. The efficacy and safety of the treatment between the two groups are compared.",[527],"Carbapenem-Resistant Enterobacteriaceae Infection",[529,530,531,532],"Colistimethate Sodium for Injection","Hospital-acquired pneumonia","Bloodstream infection","Carbapenem-resistant Enterobacteriaceae","2025-05-14",{"date":535,"type":30},"2025-05-18",{"date":537,"type":30},"2023-11-27",{"date":447,"type":21},{"name":36,"class":37},15,{"id":542,"slug":543,"hasResults":12,"nctId":544,"briefTitle":545,"officialTitle":546,"acronym":547,"eligibilityCriteria":548,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":47,"enrollmentInfo":549,"targetDuration":4,"studyType":84,"phases":551,"briefSummary":553,"conditions":554,"keywords":556,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":560,"lastUpdatePostDateStruct":561,"startDateStruct":563,"completionDateStruct":565,"leadSponsor":567,"locationsCount":4},"100588317","phase-4-a-multicenter-clinical-study-on-the-continuous-vs-intermittent-infusion-of-ceftazidime-avibactam-in-critically-ill-patients-with-severe-infections-100588317","NCT06939829","A Multicenter Clinical Study on the Continuous vs. Intermittent Infusion of Ceftazidime-Avibactam in Critically Ill Patients With Severe Infections","A Prospective, Open-Label, Randomized Controlled, Multicenter Clinical Study on Continuous vs. Intermittent Infusion of Ceftazidime-Avibactam in Critically Ill Patients With Severe Infections","AVIATOR","Inclusion Criteria:\n\n* 18-85 years old, male or female.\n* Patients who are admitted to ICU wards.\n* Patients clinically diagnosed with carbapenem-resistant organism (CRO) infections, and has been commenced on targeted therapy with ceftazidime-avibactam.\n* One or more organ dysfunction criteria in the previous 24 hours i. MAP \\\u003C 60 mmHg for at least 1 hour; ii. Vasopressors required for \\> 4 hours; iii. Respiratory support using supplemental high flow nasal prongs, continuous positive airway pressure, bilevel positive airway pressure or invasive mechanical ventilation for at least 1 hour.\n\niv. Serum creatinine concentration \\> 220 μmol\u002FL or \\>2.49 mg\u002FdL\n\nExclusion Criteria:\n\n* Patient has a known allergy to ceftazidime-avibactam.\n* Patient has received ceftazidime-avibactam for more than 48 hours during current infectious episode.\n* Patient is in severe condition or expected to survive for no more than 48 hours.\n* Patient who receives lung or heart transplant or stem cell transplant.\n* Patient is known or suspected to be pregnant.\n* Patient has previously been enrolled in the current study.\n* Other conditions which are regarded as inappropriate for enrollment.",{"count":550,"type":21},1200,[552],"PHASE4","The objective of this study is to determine whether continuous infusion of ceftazidime-avibactam (CAZ-AVI) could improve clinical outcomes in critically ill patients compared with intermittent infusion.",[555],"Patients With Critically Ill Infections",[557,558,559],"Ceftazidime-Avibactam","Continuous versus Intermittent Infusion","clinical study","2025-04-15",{"date":562,"type":30},"2025-04-23",{"date":564,"type":21},"2025-05-01",{"date":566,"type":21},"2027-12-31",{"name":36,"class":37},{"id":569,"slug":570,"hasResults":12,"nctId":571,"briefTitle":572,"officialTitle":573,"acronym":4,"eligibilityCriteria":574,"healthyVolunteers":575,"sex":17,"minAge":18,"maxAge":376,"enrollmentInfo":576,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":578,"conditions":579,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":219,"lastUpdatePostDateStruct":580,"startDateStruct":582,"completionDateStruct":584,"leadSponsor":586,"locationsCount":4},"100586825","novel-biomarkers-related-xuebijing-injection-improves-sepsis-100586825","NCT06920420","Novel Biomarkers Related Xuebijing Injection Improves Sepsis","Xuebijing Injection Regulates Endothelial Cell Panapoptosis in Treating Sepsis Through PCDHAC2\u002FBAX\u002FAIM2 Pathway","Inclusion Criteria:\n\n1. Meeting the Sepsis 3.0 diagnostic criteria;\n2. SOFA score ≥ 2 and \\\u003C 13;\n3. Signed informed consent.\n\nExclusion Criteria:\n\n1. Age \\\u003C18 years or \\>75 years;\n2. Pregnant or lactating women;\n3. Presence of severe primary diseases including malignant tumors severe hematologic disorders and HIV infection;\n4. Current use of immunosuppressants or history of organ transplantation within the past 6 months;\n5. Comorbidities that significantly affect vascular endothelial structure and function such as acute myocardial infarction.",true,{"count":577,"type":21},30,"Sepsis is a life-threatening clinical syndrome of organ dysfunction caused by dysregulation of the body's response to infection, and is a common cause of ICU admission for critically ill patients, posing a serious threat to human health. The study demonstrated that hemopexin injection significantly reduced the 28-day all-cause mortality rate of sepsis patients, and this study clarified the specific target and molecular mechanism of hemopexin injection in the treatment of sepsis, which may be of great scientific significance and clinical value for the precise treatment of sepsis and the research and development of new drugs.",[53],{"date":581,"type":30},"2025-04-09",{"date":583,"type":21},"2025-03-30",{"date":585,"type":21},"2028-12-31",{"name":36,"class":37},""]